全文获取类型
收费全文 | 54664篇 |
免费 | 3172篇 |
国内免费 | 158篇 |
专业分类
耳鼻咽喉 | 497篇 |
儿科学 | 1658篇 |
妇产科学 | 1802篇 |
基础医学 | 7353篇 |
口腔科学 | 1097篇 |
临床医学 | 7526篇 |
内科学 | 10245篇 |
皮肤病学 | 1007篇 |
神经病学 | 5398篇 |
特种医学 | 1548篇 |
外国民族医学 | 3篇 |
外科学 | 5779篇 |
综合类 | 534篇 |
一般理论 | 93篇 |
预防医学 | 5700篇 |
眼科学 | 688篇 |
药学 | 3304篇 |
中国医学 | 93篇 |
肿瘤学 | 3669篇 |
出版年
2023年 | 260篇 |
2022年 | 508篇 |
2021年 | 986篇 |
2020年 | 615篇 |
2019年 | 998篇 |
2018年 | 1209篇 |
2017年 | 837篇 |
2016年 | 919篇 |
2015年 | 1131篇 |
2014年 | 1629篇 |
2013年 | 2362篇 |
2012年 | 3547篇 |
2011年 | 3744篇 |
2010年 | 2009篇 |
2009年 | 1785篇 |
2008年 | 3256篇 |
2007年 | 3363篇 |
2006年 | 3478篇 |
2005年 | 3184篇 |
2004年 | 3027篇 |
2003年 | 2947篇 |
2002年 | 2756篇 |
2001年 | 893篇 |
2000年 | 851篇 |
1999年 | 798篇 |
1998年 | 670篇 |
1997年 | 587篇 |
1996年 | 458篇 |
1995年 | 416篇 |
1994年 | 376篇 |
1993年 | 400篇 |
1992年 | 521篇 |
1991年 | 450篇 |
1990年 | 476篇 |
1989年 | 458篇 |
1988年 | 403篇 |
1987年 | 417篇 |
1986年 | 373篇 |
1985年 | 364篇 |
1984年 | 333篇 |
1983年 | 323篇 |
1982年 | 303篇 |
1981年 | 277篇 |
1980年 | 248篇 |
1979年 | 296篇 |
1978年 | 197篇 |
1977年 | 200篇 |
1975年 | 215篇 |
1974年 | 241篇 |
1973年 | 197篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Thomas James Zirpoli Patricia Mulhearn Blasco 《Journal of developmental and physical disabilities》1988,1(1):69-77
Current medical procedures used in prenatal screening and diagnosis of handicapping conditions are reviewed. These strategies include ultrasound, amniocentesis, chorionic villus biopsy, restriction enzyme analysis, maternal serum analysis, fetoscopy, and fetal serum analysis. Along with an explanation of each method, advantages, disadvantages, and risks involved with each are provided. An understanding of these procedures by medical and educational personnel is encouraged, and the potential benefits of prenatal identification of handicapping conditions are emphasized. 相似文献
22.
23.
24.
T. Schneider W. Menke B. Fink W. Rüther K. P. Schulitz 《Archives of orthopaedic and trauma surgery》1997,116(1-2):46-49
In this study 17 patients with recurrent dislocation of the patella were followed up 10 years after their Goldthwait operation. The subjective and clinical findings were excellent or good in 70%. X-radiographs indicated osteoarthritis of the femoropatellar joint in 60%. Concerning the aetiopathological factors, we found an increased external torsion of the afflicted extremity (measured by computed tomography). 相似文献
25.
Cheryl Wallerstedt RNC MS Patricia Higgins RN PhD 《Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG》1996,25(5):389-400
Society often expects mothers and fathers to share equally in the perinatal grief process because the child was a common bond between them. Unfortunately, in perinatal grief, this is not always the case. The mother and the father can experience incongruent grieving and use discordant coping mechanisms. It is important to evaluate these differences to facilitate communication between the distraught parents. Improved communication can in turn facilitate the grieving process. 相似文献
26.
27.
In open chest dogs myocardial ischemia was induced by formation of an occlusive thrombus in the left anterior circumflex artery (LCX). Reperfusion of the LCX was achieved by infusion of the fibrin specific recombinant single-chain urokinase-type plasminogen activator (r-scu-PA). The myocardial salvage by r-scu-PA alone and in combination with the epoprostenol (prostacyclin) analog taprostene (CG 4203) was compared. There were four experimental groups: group 1 (n = 4) did not receive any treatment after LCX thrombosis; in group 2 (n = 9) at 100 min after LCX thrombosis r-scu-PA (20 micrograms.kg-1.min-1 i.v. for 30 min) was infused; in groups 3 and 4 treatment with taprostene started concomitantly with r-scu-PA infusion. The taprostene infusions lasted for 120 min and the doses were 0.1 microgram.kg-1.min-1 in group 3 (n = 6) and 0.215 microgram.kg-1.min-1 in group 4 (n = 6). Time to r-scu-PA-induced recanalisation ranged from 18-22 min with no significant difference between groups 2-4. Percent of left ventricle at risk did not differ between the groups. Infarct size as percent of the risk zone was 48.3 +/- 7.7 in group 1, 25.3 +/- 3.7 in group 2, 21.3 +/- 6.5 in group 3 and 17.1 +/- 3.5 in group 4 (p less than 0.05 groups 2-4 vs group 1). Incidence of ectopic beats increased after r-scu-PA-induced reperfusion in groups 2-4, but was significantly reduced by taprostene.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
28.
In 1985, we initiated a prospective clinical trial to evaluate the risk of recurrence for superficial bladder cancer. Up to now, 41 patients subjected to TUR have subsequently been monitored by immunocytology with a monoclonal antibody (mab 486 p) recently developed in our laboratory. Of these patients, 15 (36.6%) remained marker-negative and received no prophylactic therapy. There was only one recurrence (6.7%) in this subset of patients, whereas 10 out of 26 (38.5%) marker-positive patients have so far developed recurrent malignancies. In all cases, the conversion of immunocytological characteristics preceded visible recurrence by 2-5 months. These preliminary results indicate that immunocytology might make it possible to identify patients at low risk of recurrence more accurately than has so far been feasible with standard cytology or flow-cytometry. 相似文献
29.
30.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献